A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors

Figure 2

Vital sign data for the 3 cohorts at screening and throughout the infusion. (a) Body temperature, (b) respiration, (c) pulsation, (d) diastolic pressure, and (e) systolic pressure at the 3 different doses: 56 mg/m² (), 74 mg/m² (), and 98 mg/m² ().

(a)

(b)

(c)

(d)

(e)